Clinical Trial Update: Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3 [Phase 2]

View source ↗

Summary

Phase 2 pilot trial of sodium phenylbutyrate for Spinocerebellar Ataxia Type 3 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinocerebellar Ataxia Type 3

Drugs mentioned

• Sodium phenylbutyrate (sodium phenylbutyrate)

Snippet

Sponsor: Hospital de Clinicas de Porto Alegre | Conditions: Spinocerebellar Ataxia Type 3 | Phase 2 | Status: WITHDRAWN